Astellas licenses ADC XNW27011 from Evopoint targeting CLDN18.2

Astellas Pharma Inc., a global life sciences company, and Evopoint Biosciences, an innovative biopharmaceutical firm, have entered into an exclusive license agreement for XNW27011, a clinical-stage antibody-drug conjugate (ADC) targeting CLDN18.2.

Under this agreement, Astellas receives exclusive worldwide rights—excluding mainland China, Hong Kong, Macao, and Taiwan—to develop and commercialize XNW27011.

About XNW27011

XNW27011 is a novel investigational ADC currently in a Phase 1/2 clinical study in China. It is being evaluated in patients with CLDN18.2-expressing solid tumors, including:

• Gastric cancer
• Gastroesophageal cancer
• Pancreatic cancer

The ADC leverages a proprietary topoisomerase I inhibitor payload and linker technology—an approach that has already demonstrated success in other approved cancer therapies.

Strengthening Astellas’ Oncology Pipeline

This agreement builds on Astellas’ existing expertise in targeting CLDN18.2. The company previously introduced Vyloy, the first approved CLDN18.2-targeted therapy worldwide.

XNW27011 offers a complementary approach and enhances Astellas’ pipeline of CLDN-targeting treatments and other ADCs. It addresses areas of significant unmet medical need, particularly in gastrointestinal (GI) cancers.

Deal Structure and Financial Terms

Under the terms of the agreement:

• Evopoint will receive:
  • $130 million upfront
  • Up to $70 million in near-term payments
  • Additional milestone-based payments totaling up to $1.34 billion
  • Royalties on future net sales, if approved

Executive Statements

 “Astellas is dedicated to advancing innovative therapies for some of the most challenging-to-treat cancers, such as gastric and pancreatic cancer. XNW27011 is a promising new asset that complements Astellas’ pipeline and enhances our leading position in precision oncology. We look forward to harnessing our expertise in targeting CLDN18.2 and specialized knowledge in GI cancers to advance XNW27011 and deliver meaningful outcomes to patients.”

• Adam Pearson, Chief Strategy Officer, Astellas

 “XNW27011 is a novel investigational antibody-drug conjugate that has shown great promise in the clinic. Astellas has a proven history of developing and commercializing a strong franchise of innovative cancer therapies. We are pleased to enter into this new license agreement to further our collective goals of bringing new treatment options for patients in need worldwide.”

• Arthur Qiang, Chairman, Evopoint

About Astellas Pharma Inc.

Astellas is a global life sciences company dedicated to transforming innovative science into VALUE for patients. The company’s therapeutic focus spans:

• Oncology
• Ophthalmology
• Urology
• Immunology
• Women’s health

Astellas is recognized for delivering transformative therapies that address high unmet medical needs.

About Evopoint Biosciences

Evopoint is a cutting-edge biopharmaceutical company with strong capabilities in R&D and commercialization. Its mission is to improve human health by developing breakthrough pharmaceutical solutions for significant unmet medical needs around the world.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!